Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.

Collectively, our findings highlight the potential of targeting cell cycle timing through Myt1 inhibition as an effective strategy to enhance the efficacy of current standard cancer therapies, potentially leading to improved disease outcomes.